報價延遲最少15分鐘:2025/05/15 03:33 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.748 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
4,080.50/-5.50
|
|
企業價值
4.04M
|
| 資產負債 |
|
每股賬面淨值
-2.91
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
8.24
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/15 03:33 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells. |